Skip to main content

Table 1 Main characteristics of studies included in the meta-analysis

From: Clinicohistopathological implications of MMP/VEGF expression in retinoblastoma: a combined meta-analysis and bioinformatics analysis

Study

Country

Inclusion period

Number of patients

Gender

Eye

Age

Clinical staging

Tumor invasion

Histological type

Preoperative treatment

Detection method

Expression evaluation standards

MMP types

NOS score

Male/female

Right/left

/II+III

N0/NX

Well + moderately/poorly diff

Yun Li et al. (2006)

China

1996–2005

30

18/12

NA

Range 4 month–6 years

Median 2.9 years

13/17

17/13

11/19

NA

IHC

Proportion

MMP-1

MMP-9

8

Haiyan Li et al. (2012)

China

2002–2011

52

31/21

33/29

Range 6 month–9 years

Mean 5.1 ± 1.2 years

NA

28/24

24/28

No chemo

IHC

Proportion + intensity

MMP-1

MMP-9

VEGF

7

Siqi Yuan et al. (2010)

China

2000–2009

31

23/18

NA

Range 5 month–9 years

Median 3.3 years

NA

17/14

13/18

NA

IHC

Proportion + intensity

MMP-1

VEGF

6

Mohan Adithi et al. (2006)

India

2000–2003

55

35/20

29/26

Range 1 month–14 years

Median 2 years

0/55

23/32

21/34

No chemo

IHC

Proportion

MMP-2

MMP-9

8

Yang Yang et al. (2013)

China

2001–2012

45

23/22

24/21

Range 2 month–8 years

36/9

26/19

17/28

No chemo

No radio

IHC

Proportion

MMP-2

6

Lin Zhou et al. (2010)

China

1989–2010

40

23/17

17/23

Range 4 month–18 years

Median 2.9 years

NA

27/13

15/25

No chemo

No radio

IHC

Proportion + intensity

MMP-2

MMP-9

VEGF

6

Jun Liang et al. (2017)

China

2011–2016

100

66/34

NA

Range 4 month–11 years

Median 4.2 years

39/61

NA

55/45

NA

IHC

Proportion + intensity

MMP-9

VEGF

8

Yan Sun et al. (2014)

China

2000–2011

56

29/27

NA

Range 3 month–7 years

Mean 3.6 years

20/16

28/28

31/25

No chemo

IHC

Proportion + intensity

MMP-9

7

Zhen Ge et al. (2007)

China

1995–2005

32

19/13

NA

Range 4 month–10 years

Median 3.1 years

NA

21/11

12/20

No chemo

IHC

Proportion + intensity

MMP-9

VEGF

6

Zixu Wu et al. (2011)

China

2000–2010

41

23/18

NA

NA

29/12

24/17

20/21

NA

IHC

Proportion + intensity

MMP-9

6

Jia Yu et al. (2009)

China

1990–2006

47

25/12

20/27

Range 6 month–10 years

NA

32/15

17/30

No chemo

No radio

IHC

Proportion + intensity

MMP-9

VEGF

6

Yuejun Liu et al. (2014)

China

2010–2014

30

18/12

NA

Mean 5.2 years

NA

17/13

12/18

No chemo

IHC

Proportion + intensity

MMP-9

6

Ying Jiang et al. (2004)

China

1999–2002

22

NA

NA

Range 2 month–5 years

Mean 2.4 years

NA

14/8

8/14

No chemo

No radio

IHC

Proportion

VEGF

7

Nermeen S Youssef et al. (2014)

Egypt

2009–2013

56

24/32

23/40

Mean 20.94 m ± 11.75 months

NA

26/30

36/20

No preoperative adjunctive treatments

IHC

percentage

VEGF

8

Lijuan Meng et al. (2011)

China

NA

48

27/21

22/26

Range 5 month–8y

NA

21/27

19/29

No chemo

No radio

IHC

Proportion × intensity

MMP-9

VEGF

6

Li Fang et al. (2010)

China

2000–2007

33

18/15

14/19

Range 6 month–9 years

NA

22/11

12/21

No chemo

No radio

IHC

Proportion + intensity

VEGF

6

  1. m month, y year, IHC immunohistochemistry, NA not available, chemo chemotherapy, radi radiation therapy, diff differentiation, N0: absent local invasion, Nx optic nerve, optic nerve, choroidal, or scleral invasion, Proportion percentage of positive cells, intensity staining intensity of positive cells